Dear Dr. Hahn:

We are experts in virology, epidemiology, vaccinology, infectious disease, clinical care and public health. A vaccine(s) is needed to curtail the COVID-19 pandemic. We are committed to promoting the broad uptake of safe and effective COVID-19 vaccines. The need is urgent but all vaccines must be rigorously studied to determine whether their benefits exceed their risks.

For this reason, we urge that COVID-19 vaccines are made widely available only after the Food and Drug Administration (FDA) has been able to evaluate safety and efficacy data from completed Phase 3 clinical trials. The FDA’s review must be as thorough as has been the case for previous vaccine candidates. As transparency will be critical for fostering public confidence and maximizing vaccine use, the open meetings of the FDA’s Vaccines and Related Biologics Product Approval (VRBPAC) Committee must be an essential part of the authorization and approval processes.

Several COVID-19 vaccine candidates are now in Phase 3 trials. We hope one or more of them will soon prove to be both safe and effective. The decisions to fund and produce many millions of doses ahead of the trial results should save many months in providing approved vaccines to the American public. In short, productive collaborations between scientists, the pharmaceutical industry and the federal government may bring us to a remarkable and historic achievement – the creation of a vaccine within a year after this pandemic virus was first identified.

But an effective vaccine will only be truly useful if a large proportion of the public is willing to take it. Surveys have consistently shown that a significant fraction of Americans, from across the political spectrum, is reluctant to accept a COVID-19 vaccine. Some long-standing concerns about vaccine safety in general have no scientific foundation. However, more than 60% of US voters prefer that a COVID-19 vaccine be thoroughly evaluated before it is made available, even if doing so delays its roll-out. A particular concern applies to communities of color, where historical medical inequities are also likely to reduce vaccine uptake. Actively involving these and other communities that are at high risk of severe COVID-19 disease is essential to curtailing the pandemic. Similar considerations apply to vaccine distribution, which must not be determined by either an ability to pay or social influence.

The foundation of public confidence in vaccine safety has long been, and must remain, the well-established and trusted FDA approval procedures. The public is typically and rightly able to comment on vaccine approval. It is important that investigators share Phase 3 trial design details. For example, Data Safety Monitoring Boards apply predetermined “stopping rules” to decide whether a study should be terminated early based on the detection of early benefits, the
likelihood of no benefit, or the emergence of serious safety problems. These stopping rules should be publicly available. There must also be continuous monitoring for unexpected severe side effects that might only become apparent after large numbers of people are vaccinated.

To maximize the use of a COVID-19 vaccine(s) by the American people, it is therefore essential that the science and public health communities work with the federal government to increase public confidence in any approved or authorized product. However, we can only perform as advocates if we ourselves are persuaded that the vaccine(s) truly is safe and effective. We must be able to explain to the public what we know and what we don’t know about these vaccines. For that to happen, we must be able to witness a transparent and rigorous FDA approval process that is devoid of political considerations. We ask that company executives and government officials take due note of these key points.

The COVID-19 virus has now killed more than 150,000 people in the USA alone. We need a safe and effective vaccine urgently, but any lack of trust in its properties could significantly compromise rollout. We look forward to the day when we can actively promote a safe and effective COVID-19 vaccine to the American people, based on our full confidence in its public health impact.

Signed,

Lilian Abbo, University of Miami
Jimi Adams, University of Colorado Denver
Terry Adirim, Schmidt College of Medicine at Florida Atlantic University/Formerly Department of Defense
Bisher Akil, Chelsea Village Medical, P.C.
Sandra Albrecht, Columbia University
G. Caleb Alexander, Johns Hopkins Bloomberg School of Public Health
Matthew Aliota, University of Minnesota
Todd Allen, Ragon Institute of MGH, MIT and Harvard
Nelson Atehortua De la Pena, Jackson State University
Su Aung, UCSF
Kathleen Bachynski, Muhlenberg College
Stefan Baral, Johns Hopkins School of Public Health
Joshua Barocas, Boston Medical Center
Peter Barr-Gillespie, Oregon Health & Science University
Ingrid Bassett, Massachusetts General Hospital
Sanjay Basu, Harvard medical school
Robert Bazell, Yale School of Medicine
Robert Bednarczyk, Emory University Rollins School of Public Health
Amy Bei, Yale School of Public Health
Kiran Belani, Childrenâ€™s hospital of Minnesota
Rachel Bender Ignacio, University of Washington
Karen Benker, SUNY Downstate School of Public Health
Wendy Berg, Children’s Minnesota
Michelle Berlin, OHSU
Akiko Iwasaki, Yale University School of Medicine
Peter Jacobson, University of Michigan School of Public Health
Jana Jarolimova, Massachusetts General Hospital
Jacky Jennings, Johns Hopkins School of Medicine
Prabhat Jha, University of Toronto
Nikolaus Jilg, Massachusetts General Hospital
Esther John, Stanford University School of Medicine
R. Paul Johnson, Emory University
T Stephen Jones, Centers for Disease Control and Prevention (retired)
Jeb Jones, Emory University
Catherine Jones, Tulane University School of Medicine
Brian Joyce, Northwestern University
James G Kahn, UCSF
Rizwan Kalani, University of Washington Medical Center
Norty Kalishman, None
Jeremy Kamil, Louisiana State University Health Sciences Center Shreveport
Amy Kapczynski, Yale Law School
Robert Kaplan, UCLA
Jonathan Karn, Case Western Reserve School of Medicine
Michael Katz, Columbia University, Stanford University
Judith Katzburg, NA
Matthew Kavanagh, Georgetown University
Dean Kedes, University of Virginia
Elizabeth Kern, National Jewish Health
Jean Kerver, Michigan State University
Joan King-Angell, Lifelong Medical Care
P. J. Klasse, Weill Cornell Medicine, Cornell University
Albert Ko, Yale School of Public Health
Roya Kohani, Harvard Medical Alumnae/UCSD School of Medicine
Michael Kolber, University of Miami Miller School of Medicine
Kristin Kranz, NA
Nancy Krieger, Harvard T.H. Chan School of Public Health
James Krieger, University of Washington
Danuta Krotoski, Self-Employed
Allison Kuipers, University of Pittsburgh
Daniel Kuritzkes, Brigham and Women's Hospital/Harvard Medical School
Joseph Kurland, Children's Minnesota
Jeanette LaBarre, Children's Minnesota
Jess Ladd, Self-employed
Andrew Lai, UCSF Health
Lisa M Lee, Virginia Tech
Juan Leon, Emory University
Jeffrey Levi, George Washington University
George Lewis, Institute of Human Virology
Joel Lexchin, University Health Network
Renfeng Li, Virginia Commonwealth University
Tracy Lieu, Kaiser Permanente
W Liles, University of Washington
Brett Lindenbach, Yale University
Walter Ian Lipkin, Columbia University
Marc Lipsitch, Harvard Chan School of Public Health
Yang Liu, Institute of Human Virology, University of Maryland Baltimore
Martha Livingston, SUNY Old Westbury
Bernard Lo, University of California San Francisco
Shahin Lockman, Brigham and Women's Hospital
Johanna Lolax, The George Washington University and Simmons University
Paul Luciw, University of California - Davis
Jing Luo, University of Pittsburgh
Mark Lurie, Brown University
Peter Lurie, Center for Science in the Public Interest
Boris Lushniak, University of Maryland School of Public Health
Katherine Luzuriaga, University of Massachusetts Medical School
Jay Maddock, Texas A&M University
Lisa Maier, National Jewish Health
TOMAS MAIRA-LITRAN, BWH-HARVARD MEDICAL SCHOOL
Barry Make, National Jewish Health
Lloyd Mancl, University of Washington
Mohan Manjegowda, University of Virginia
JoAnn Manson, Harvard Medical School and Harvard T.H. Chan School of Public Health
Julia Marcus, Harvard Medical School
Edgar Marcuse, University of Washington
Serese Marotta, Families Fighting Flu
Duncan Maru, Mount Sinai School of Medicine and NYC H&H / Elmhurst Hospital
Rani Marx, Initiative for Slow Medicine
Lawrence Mayer, private
Joseph (Mike) McCune, University of California, San Francisco
Andrew Mehle, University of Wisconsin Madison
Michelle Mello, Stanford University
Miriam Merad, Mount Sinai School Of MÂ©decine
Cheryl Merzel, New York University School of Global Public Health
Deborah K Mielke, Fairview- University of MN
Steven Miles, University of Minnesota
Suellen Miller, Ucsf
Supriya Misra, NYU School of Global Public Health
Dawn Misra, Michigan State University
John Modlin, Geisel School of Medicine at Dartmouth
Amir Mohareb, Massachusetts General Hospital
Supriya Mohile, University of Rochester
David Montefiori, Duke University Medical Center
John Moore, Weill Cornell Medicine, New York
Julie Morita, Chicago Department of Public Health
Michele Morris, University of Miami Miller School of Medicine
Anne Moscona, Columbia University
Walther Mothes, Yale University
Herb Myers, Retired
K M Venkat Narayan, Emory University
Sandra Nelson, Massachusetts General Hospital
Lorene Nelson, Stanford University School of Medicine
Bud Nicola, University of Washington School of Public Health
Douglas Nixon, Weill Cornell Medicine
Robert Noble, retired Professor of Medicine, Division of Infectious Diseases
Ali Nouri, Federation of American Scientists
Dave O'Connor, University of Wisconsin-Madison
Shelby O'Connor, University of Wisconsin-Madison
Paul Offit, Childrenâ€™s Hospital of Philadelphia
Bisola O. Ojikutu, Brigham and Women's Hospital
Douglas Opel, University of Washington School of Medicine
Walter Orenstein, Emory University School of Medicine
Karin Pacheco, National Jewish Health, and University of Colorado School of Public Health
Alisa Padon, Public Health Institute
Kimberly Page, University of New Mexico Health Sciences Center
Sunil Parikh, Yale School of Public Health
Tyan Parker Dominguez, USC Suzanne Dworak-Peck School of Social Work
Wendy Parmet, Northeastern Univ.
Adina Parsley, retired
Deborah Passey, University of Utah
Rena Patel, University of Washington
Kavita Patel, Brookings Institution
Sonali Paul, University of Chicago Medicine
Cynthia Pearson, National Women's Health Network
HECTOR PEREZ, OSDE
Steven Pergam, University of Washington
janet perlman, UCSF
Dennis M. Perrotta, Texas Department of State Health Services
Sue Peschin, Alliance for Aging Research
Gerald Pier, Brigham and Women's Hospital
Kent Pinkerton, University of California, Davis
Amy Pisani, Vaccinate Your Family
Stephen Plank, Ex Harvard School of Public Health faculty; Rockefeller Foundation
Rebeca Plank, Brigham and Women's Hospital
Travis Porco, UCSF
Tonia Poteat, University of North Carolina School of Medicine
John Potter, Fred Hutchinson Cancer Research Center
Enrique Pouget, CUNY
Alexis Powell, University of Miami Miller School of Medicine
Mark C. Poznansky, Massachusetts General Hospital and Harvard Medical School
Lou Priem, Bassett Healthcare
Mary Procidano, Fordham University
Selvi Rajagopal, Johns Hopkins University School of Medicine
Delbert Raymond III, Eastern Michigan University
Mathew Reeves, Michigan Sttate University
Dorit Reiss, University of California, Hastings College of the Law
Matt Reynolds, University of Wisconsin-Madison
Beth Rezet, CHOP
Josiah Rich, Brown University
Douglas Richman, University of California San Diego
Josh Rising, Rising Health Strategies
Stefano Rivella, CHOP-UPenn
Anthony Robbins, National Vaccine Program
Gregory Robbins, MGH
Christopher Robertson, Boston University
Saul Rodriguez, Syneos Health
Charles Rosen, University of California, Irvine, School of Medicine
Jacob Rosenberg, MGH
Joseph Ross, Yale University
Heather Ross, Arizona State University
Mitchel Rothholz, American Pharmacists Association
Emily Rugel, University of Sydney
H. Earl Ruley, Vanderbilt University School of Medicine
Tamara Rushovich, Harvard T.H. Chan School of Public Health
Dave Ruud, Retired
Sarah Rybicki, University of Minnesota, School of Public Health
Parya Saberi, University of California, San Francisco
Mohammad Sajadi, Institute of Human Virology at the University of Maryland School of Medicine
Tony Salloum, University of Miami Miller school of medicine
Daniel Salmon, Institute for Vaccine Safety, Johns Hopkins University Bloomberg School of Public Health
Mario Santiago, University of Colorado
Ana Santos Rutschman, Saint Louis University School of Law
Paul Sax, Brigham and Women's Hospital, Harvard Medical School
Charles Schade, Retired
William Schaffner, Vanderbilt University Medical Center
Laura Schmidt, School of Medicine, University of California at San Francisco
Victor Schoenbach, UNC Gillings School of Global Public Health
Robert Schooley, University of California San Diego
Pamela Schreiner, University of Minnesota
John Scott, University of Washington
Grace Sembajwe, Northwell Health
Ellen Shaffer, UCSF; CPATH (Center for Policy Analysis on Trade & Health)
Saate Shakil, UNIVERSITY OF WASHINGTON DIVISION OF CARD
Angela Shen, CHOP
Michael Siegel, Retired. Formerly at Children's Hospital of Los Angeles
Lynn Silver, Public Health Institute
Ross Silverman, Indiana University Fairbanks School of Public Health
Michael Silverstein, retired
Robin Simon, Wake Forest University
Geoffrey Smith, Albion College (AB), University of Vermont College of Medicine (MD), Harvard School of Public Health (MPH)
Deborah Wexler, Immunization Action Coalition
Judith White, University of Virginia
Cynthia Whitney, Emory University
Robin Wilson, Temple University
Gabriel Wilson, Woodland Heights Medical Center
Elizabeth Wonderlich, Southern Research
Susan Wood, George Washington University, Milken Institute School of Public Health
Matthew Wynia, University of Colorado School of Medicine and Colorado School of Public Health
Jiayi Xu, Mount Sinai
Reza Yaesoubi, Yale School of Public Health
Kimon Zachary, Massachusetts General Hospital and Harvard Medical School
Stephanie Zaza, American College of Preventive Medicine
Steven Zeichner, University of Virginia
Nicole Zeisig, Memorial Hermann
Patricia Zettler, The Ohio State University
Moritz College of Law
Pan Zheng, Institute of Human Virology, University of Maryland Baltimore
Diana Zuckerman, National Center for Health Research